RT Generic
T1 Natural Killer Cell Recognition of Melanoma: New Clues for a More effective immunotherapy
A1 Tarazona, Raquel
A1 Duran, Esther
A1 Solana, Rafael
K1 Melanoma
K1 Immunotherapy
K1 Natural killer cells
K1 Adoptive transfer
K1 Checkpoint blockade
AB Natural killer (NK) cells participate in the early immune response against melanoma and also contribute to the development of an adequate adaptive immune response by their crosstalk with dendritic cells and cytokine secretion. Melanoma resistance to conventional therapies together with its high immunogenicity justifies the development of novel therapies aimed to stimulate effective immune responses against melanoma. However, melanoma cells frequently escape to CD8 T cell recognition by the down-regulation of major histocompatibility complex (MHC) class I molecules. In this scenario, NK cells emerge as potential candidates for melanoma immunotherapy due to their capacity to recognize and destroy melanoma cells expressing low levels of MHC class I molecules. In addition, the possibility to combine immune checkpoint blockade with other NK cell potentiating strategies (e.g., cytokine induction of activating receptors) has opened new perspectives in the potential use of adoptive NK cell-based immunotherapy in melanoma.
PB Frontiers Research Foundation
SN 1664-3224
YR 2015
FD 2015-12-14
LK http://hdl.handle.net/10668/19219
UL http://hdl.handle.net/10668/19219
LA en
NO Tarazona R, Duran E, Solana R. Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol. 2016 Jan 7;6:649
NO We apologize to our colleagues whose work was not cited due to space limitations. This work was supported by grants SAF2009-09711 and SAF2013-46161-R (to RT) from the Ministry of Economy and Competitiveness of Spain, PS09/00723 and  PI13/02691 (to RS) from Spanish Ministry of Health and CTS 208 from Junta de Andalucia (to RS) and grants to INPATT research group (GRU10104 and GR15183) and PRI09A029 from Junta de Extremadura and University of Extremadura (to RT and ED) cofinanced by European Regional Development Funds (FEDER). This work was also supported by contracts QLRT-2001-00668 (Outcome and Impact of Specific Treatment in European Research on Melanoma, OISTER) and LABPOLE project from the Ministry of Economy and Competitiveness cofinanced by FEDER.
DS RISalud
RD Apr 11, 2025